# A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma

Source: https://onco.cc/trials/nct07791758/  
OnCo record `nct07791758` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of bevacizumab, oxaliplatin and capecitabine in colorectal cancer, run by Nanjing Leads Biolabs Co.,Ltd, not yet recruiting.

## Summary

A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma is a phase 1/2, randomised interventional study registered as NCT07791758 by Nanjing Leads Biolabs Co.,Ltd, with a registry enrolment figure of 369 participants, started 2026-09-04 and due to reach its primary completion in 2030-09-04. Interventions recorded: LBL-024 for Injection; Bevacizumab injection; Oxaliplatin injection; Capecitabine tablets; Fruquintinib Capsules. Conditions listed: Metastatic Colorectal Carcinoma. Primary outcome: Objective Response Rate (ORR); Occurrence of adverse event (AE) and serious adverse event (SAE). Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07791758
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 369

## Sources

- ClinicalTrials.gov NCT07791758: https://clinicaltrials.gov/study/NCT07791758

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07791758.json